Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-092-1 | CAS number: 1175006-92-4
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - dermal (%):
- 0.494
Additional information
Toxicokinetic Assessment Mexoryl SBO
No ADME with the Mexoryl SBO are available but a dermal absorption study is available.
However, in one acute and one repeated dose oral toxicity study rats show signs of systemic toxicity. Also in one teratogenicity study in the rabbit with Mexoryl SBO systemic toxicity was seen leading to the conclusion that the test substance is bioavailable after oral application.
After dermal application of 1000 mg test substance/kg bw in a rat repeated dose toxicity study limited systemic effects could be observed. The octanol/water partition coefficient of 3.2 indicates lipophilic property of the substance and it can be assumed that the substance penetrates to some extend though the skin. However, due to the low toxicological potential of the test substance only very limited clinical signs could be observed after dermal exposure.
In the in vitro percutaneous penetration (OECD 428) study tetrahydrojasmonate at 4% in a typical ‘Leave-on’ skin care formulation penetrated through human dermatomed skin at a very slow rate. The extent of tetrahydrojasmonate penetration through human skin amounted to only 0.494 ± 0.520% (0.403 ± 0.424 μg/cm2) of the applied dose, after 24 hours.
The mean total systemically available dose of tetrahydrojasmonate (remaining epidermis plus dermis and receptor fluid) was 2.92 ± 1.52% of the applied dose (corresponding to 2.39 ± 1.24 μg/cm2).
The substance Mexoryl SBO is a liquid at room temperature with the vapour pressure of 988 Pa. Inhalation exposure might be possible via evaporation and as aerosol.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
